Already missing FDA's vocal commish? Scott Gottlieb will keep chiming in on drug pricing in new role
As head of the FDA, Scott Gottlieb has been outspoken about drug pricing, chiming in on an area that is typically tangential to the agency commissioner’s purview. In the first announcement of his next steps — made one day before he’s scheduled to officially end his shorter-than-expected tenure — Gottlieb says he’s returning to the American Enterprise Institute as a resident fellow focused on these exact issues.
Basic subscription required
Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.